pipelin timelin
messag report larg in-lin quarter versu estim affirm
guidanc quarterli result surpris investor
manag alreadi set expect multipl occas respect
pipelin manag also affirm timelin gadvair action date
biosimilar neulasta action date note believ re-
inspect biosimilar neulasta manufactur facil bangalor necessari even
spite recent issu maintain buy rate
result revenu line forecast consensu
respect segment american revenu
y/i street estim off-set european revenu
y/i consensu european strength driven
double-digit y/i growth core market franc itali spain poland adj
ep slightli higher our/street estim note
manag alreadi set expect result last earn call
april investor day note ep would amount total
ep vs given re-affirmed guidanc ep equal
midpoint ep guidanc
gadvair manag note fda continu review gadvair applic
seek clarif compani respons submit march
though remain confid science-rel issu continu anticip
approv action date continu expect product ab-
rate state commerci manufactur respect potenti
launch ramp anticip differ dynamic/uptak vs gcopaxon given differ
distribut network regular rx refil advair competit sandoz
gadvair applic receiv although compani expect
conduct small bioequival bridg studi believ readi launch
hik/vec announc fda upheld origin request
addit clinic endpoint studi delay submiss approval/
launch like teva indic would submit applic
cipla commenc clinic trial anticip file may-aug
time-frame short receiv june approv believ compani
could potenti sole gener manufactur extend period
biosimilar neulasta biocon announc bangalor facil receiv
relat pai biosimilar neulasta see note publish
biocon could impli neulasta biosimilar delay citat relat
drug product/fil finish potenti impact biosimilar neulasta time tad
remain question like biocon indic observ larg
routin fall categori continu improv alreadi respond
like indic need re-inspect prior approv howev even
re-inspect requir given slower ramp biosimilar like mute
contribut guidanc month potenti slow ramp product
believ could still achiev guidanc even short delay
page analyst certif import disclosur
revefenacin mid-cycl review april revefenacin pdufa
manag note review routin outstand question
continu expect on-tim novemb approv previous spoke
two pulmonari consult regard data market opportun revefenacin
lama expert confid phase studi result good enough
approv believ anyth unexpect data see note
publish posit consult feedback revefenacin opportun
estim revefenacin market opportun could mean roughli
peak revenu though caveat profit would share profit-
share agreement
model chang manag maintain guidanc revenu rang
adj ep rang revenu forecast
move vs prior adj ep remain rang
bound guidanc maintain buy rate
valu use rel valuat ev/ebitda methodolog use ev/
ebitda multipl appli ebitda estim arriv
price target valuat repres potenti upsid current level
believ premium multipl gener group specialti group
appropri given risk/benefit profil diversif outsid
pipelin contain biosimilar hard-to-manufactur complex product
risk price target includ longer-than-expect fda approv timelin
higher expect cost failur success introduc new product market
failur penetr highli generic market obtain approv addit
competit epipen market addit gener price headwind inabl
compani pay debt manufactur inspect key plant
perform third-parti cmo clinic develop risk inabl
compani gain approv fda biosimilar product gener advair
limit intellectu properti ip protect control trade secret technolog
innov abil competitor independ develop similar better proprietari
inform techniqu disclos publicli success compet therapi
product becom avail medicar medicaid insur increas
effort manag drug spend econom weak impact unemploy commerci
insur coverag util forecast error determin mylan market
opportun risk includ compani may requir substanti addit fund
may financ futur cash need primarili public privat offer debt financ
strateg collabor may dilut stockhold compani
page analyst certif import disclosur
servic
total servic
revenu
revenu
litigation-rel
acquisition-rel charg
restructur special item oper
depreci amort
sale/merg expenses/adjust
interest dividend incom
equiti method loss clean energi invest
restructur special item
discountinu op net tax
total servic
compani report guggenheim secur llc estim
page analyst certif import disclosur
